Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of R21 + RH5.1 + R78C Malaria Vaccine in Burkina Faso
NCT06958198Phase 1Active, not recruiting
- Sponsor
- University of Oxford
- Start
- Sep 2025
- Primary completion
- Mar 2027
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of R21/Matrix-M, RH5.1 and R78C in malaria (6 arms), sponsored by University of Oxford. Primary endpoints: Solicited Adverse Events, Unsolicited Adverse Events at Day 196 and 1 more. Started Sep 2025; status: active, not recruiting.
02
Drugs
R21/Matrix-MRH5.1R78C
03
Conditions
malaria
Beyond the preview
Go deeper on NCT06958198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06958198.